Fig. 3From: Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysisCumulative incidence curves of new onset cardiac complications and all-cause mortality in cancer patients stratified by PD-1 or PD-L1 inhibitor use after 1:2 propensity score matchingBack to article page